OKUR
OnKure Therapeutics, Inc.Company with tickers: OKUR
CIK
1637715
CUSIP
68277Q105
Shares Outstanding
40,395,480
Website
https://www.onkure.com
13F Activity (30d)
7 filings
6 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $15,615,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Research & Development | $11,707,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Operating Income | $-15,615,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Net Income | $-15,157,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| EPS (Basic) | $-1.11 | USD/shares | 2026-03-31 | 10-Q | 2026-05-05 |
| EPS (Diluted) | $-1.11 | USD/shares | 2026-03-31 | 10-Q | 2026-05-05 |